Ticker

The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%. However, the biotech sector has gained +33-35% in the same period - and many predict things are just getting started. For those seeking a broad biotech exposure,... Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the…

The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%.

Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity offering.

DAFNA Capital Management LLC sold 34,405 shares of iShares Biotechnology ETF (IBB) Quarter-end position value decreased by $3.31 million, reflecting both trading and stock price effects Trade represented a 1.3% reduction of 13F reportable assets under management Post-trade holding: 68,095 shares valued at $11.49 million IBB accounted for 2.67% of fund AUM after the trade, placing it outside the fund's top five…

Bank of America Corp DE lowered its position in iShares Biotechnology ETF (NASDAQ: IBB) by 4.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,893,841 shares of the financial services provider's stock after selling 243,108 shares during the